SPRAVATO - Johnson & Johnson
3 days ago · Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate response to ...
FDA approves first-of-its-kind nasal spray for severe depression
Spravato is now cleared to use by itself after years of clinical trials. By Andrew Paul Posted 24 Hours Ago Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine ...
FDA approves Johnson & Johnson nasal spray Spravato for …
3 days ago · Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
FDA Approves Spravato Nasal Spray for Treatment-Resistant …
2 days ago · WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson. Spravato is the first and only ...
FDA approves Spravato, first monotherapy nasal spray to treat
3 days ago · Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.
Janssen Announces U.S. FDA Approval of SPRAVATO - Johnson & Johnson
Aug 3, 2020 · SPRAVATO ® is approved in the United States, in conjunction with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with MDD with acute suicidal ideation or behavior.
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO
Titusville, New Jersey, July 22, 2024 – Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO® (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD).
J&J's Spravato Wins FDA Approval, Stands as a Game-Changer for …
3 days ago · New Brunswick, NJ January 21, 2025 Johnson & Johnson has finally got its breakthrough depression treatment, Spravato (esketamine), approved by the U.S. FDA (Food and Drug Administration) as ...
FDA signs off on Johnson & Johnson's Spravato as a monotherapy
2 days ago · Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA has blessed the nasal spray to be used as a monotherapy for major ...
FDA Approves Johnson & Johnson's Spravato as Standalone …
2 days ago · The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment for adults with treatment-resistant depression. This landmark decision makes Spravato the first-ever monotherapy of its kind, offering hope for individuals who have not responded to at least two standard antidepressant therapies.
- Some results have been removed